Optimising Asparaginase Use and Managing Hypersensitivity in Australasia—A Clinical Practice Guideline From the Australian and New Zealand Children's Haematology/Oncology Group

IF 1.4 4区医学 Q2 PEDIATRICS

Journal of paediatrics and child health Pub Date : 2026-10-15 Epub Date: 2026-08-10 DOI:10.1111/jpc.70531

Matthew J. O'Connor, Michelle Martin, Sarah M. Trinder, Draga Barbaric, Diane Hanna, Chow Y. Lai, Michael P. Osborn, Tim Prestige, Bryony Ross, Leanne Super, Thomas Walwyn, Stacie S. Wang, Andrew Wood, Andrew S. Moore, Rishi S. Kotecha, Siobhan Cross

{"title":"Optimising Asparaginase Use and Managing Hypersensitivity in Australasia—A Clinical Practice Guideline From the Australian and New Zealand Children's Haematology/Oncology Group","authors":"Matthew J. O'Connor, Michelle Martin, Sarah M. Trinder, Draga Barbaric, Diane Hanna, Chow Y. Lai, Michael P. Osborn, Tim Prestige, Bryony Ross, Leanne Super, Thomas Walwyn, Stacie S. Wang, Andrew Wood, Andrew S. Moore, Rishi S. Kotecha, Siobhan Cross","doi":"10.1111/jpc.70531","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Asparaginase is a critical component of modern multi-agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To develop a clinical practice guideline for the use of asparaginase products in the Australasian context.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This clinical practice guideline was developed following consultation and a review of the available published data and is designed to standardise treatment across the region.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>This paper reports the position of the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) on key areas including established and new asparaginase products and their use in Australasia, monitoring and interpretation of serum asparaginase activity, care in the setting of hypersensitivity and management of suboptimal asparagine depletion.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This clinical practice guideline will assist clinicians in the Australasian region who provide care to children, adolescents and young adults receiving asparaginase therapy.</p>\n </section>\n </div>","PeriodicalId":16648,"journal":{"name":"Journal of paediatrics and child health","volume":"62 10","pages":"1913-1920"},"PeriodicalIF":1.4000,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jpc.70531","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of paediatrics and child health","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jpc.70531","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Asparaginase is a critical component of modern multi-agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes.

Objectives

To develop a clinical practice guideline for the use of asparaginase products in the Australasian context.

Methods

This clinical practice guideline was developed following consultation and a review of the available published data and is designed to standardise treatment across the region.

Results

This paper reports the position of the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) on key areas including established and new asparaginase products and their use in Australasia, monitoring and interpretation of serum asparaginase activity, care in the setting of hypersensitivity and management of suboptimal asparagine depletion.

Conclusions

This clinical practice guideline will assist clinicians in the Australasian region who provide care to children, adolescents and young adults receiving asparaginase therapy.

查看原文本刊更多论文

优化澳大利亚天冬酰胺酶的使用和管理过敏——澳大利亚和新西兰儿童血液学/肿瘤学小组的临床实践指南。

背景：天冬酰胺酶是儿科急性淋巴细胞白血病和淋巴细胞淋巴瘤现代多药化疗方案的重要组成部分，暴露不足导致患者预后不良。目的：制定在澳大利亚使用天冬酰胺酶产品的临床实践指南。方法：本临床实践指南是在咨询和审查现有已发表的数据后制定的，旨在使整个地区的治疗标准化。结果：本文报道了澳大利亚和新西兰儿童血液学/肿瘤学组（ANZCHOG）在关键领域的立场，包括已建立的和新的天冬酰胺酶产品及其在澳大利亚的使用，血清天冬酰胺酶活性的监测和解释，过敏背景下的护理和次优天冬酰胺耗竭的管理。结论：该临床实践指南将帮助澳大利亚地区的临床医生为接受天冬酰胺酶治疗的儿童、青少年和年轻人提供护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of paediatrics and child health 医学-小儿科

CiteScore

2.90

自引率

5.90%

发文量

487

审稿时长

3-6 weeks

期刊介绍： The Journal of Paediatrics and Child Health publishes original research articles of scientific excellence in paediatrics and child health. Research Articles, Case Reports and Letters to the Editor are published, together with invited Reviews, Annotations, Editorial Comments and manuscripts of educational interest.